Back to the drug test guide

Benzodiazepines Test Evidence

Has Caused a False Positive

Efavirenz

Source Blank et al., Clin Infect Dis 2009

What It Found

  • Among 50 people taking efavirenz, 49 screened positive on at least one test, compared with one of 50 who were not taking it.
  • The investigators identified 8-hydroxyefavirenz as the cross-reacting metabolite.

Keep in Mind

  • The finding applies to susceptible assays and does not give an individual probability for a different test.

Test Studied

  • Urine benzodiazepine immunoassays compared in HIV care

Oxaprozin

Source Fraser and Howell, J Anal Toxicol 1998

What It Found

  • After a single 1,200 mg dose of oxaprozin, 36 of 36 specimens from 12 people screened positive on EMIT and CEDIA.
  • Abbott FPIA was positive in 35 of 36.
  • Oxaprozin also reacted when added to drug-free urine.

Keep in Mind

  • All three historical assays used a 200 ng/mL cutoff.

Test Studied

  • EMIT dau, Abbott FPIA and BMC CEDIA benzodiazepine assays

Source Nishikawa et al., J Anal Toxicol 1999

What It Found

  • A separate letter reported interference on urine benzodiazepine immunoassays and no interference on a receptor assay.

Keep in Mind

  • The PubMed citation lacks the primary assay names and quantitative results.

Test Studied

  • Historical urine benzodiazepine immunoassays and a receptor assay

Also cited: Pulini, JAMA 1995; Camara et al., Clin Chem 1995

Pirfenidone

Both sources Pope et al., J Heart Lung Transplant 2018 Saitman et al., J Anal Toxicol 2026

What It Found

  • A lung transplant evaluation prompted investigation of a positive benzodiazepine screen in a patient on pirfenidone.
  • The drug also produced a positive response when added to urine in the laboratory.

Source Pope et al., J Heart Lung Transplant 2018

Keep in Mind

  • This report concerns a specific CEDIA method and a small number of clinical observations.

Test Studied

  • CEDIA benzodiazepine immunoassay

Fluoxetine

Both sources Callaghan and Rappaport, Pediatr Emerg Care 2021 Saitman et al., J Anal Toxicol 2026

What It Found

  • A case report described an unexpected benzodiazepine result in a child taking fluoxetine.

Source Callaghan and Rappaport, Pediatr Emerg Care 2021

Keep in Mind

  • One clinical report.
  • The authors did not isolate fluoxetine in a spiking experiment, and a positive screen cannot be attributed to it solely from the medication list.

Test Studied

  • PROFILE-V MEDTOXScan benzodiazepine screen

Diazoxide

Source Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

What It Found

  • The 2009 comparison lists reactivity at 300 ng/mL for Diazoxide on the Biosite Triage screen.

Keep in Mind

  • This laboratory comparison used historical reagents.
  • It gives no frequency after routine use.
  • The result depends on the reagent, the cutoff and the concentration in the specimen.

Tests Studied

  • Biosite Triage Benzodiazepines screen, Krasowski et al. supplement, C
  • BENZOS, row 68

Flurbiprofen

Source Joseph et al., J Anal Toxicol 1995

What It Found

  • Testing urine with high concentrations of flurbiprofen produced a signal the authors flagged as a potential cause of false-positive TDx benzodiazepine results.

Keep in Mind

  • Bench testing on a historical platform does not establish that ordinary doses cause this result on current screens.

Test Studied

  • Abbott TDx benzodiazepine fluorescence polarization immunoassay

Fluspirilene

Source Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

What It Found

  • The 2009 comparison lists reactivity at 100,000 ng/mL for Fluspirilene on the Biosite Triage screen.

Keep in Mind

  • This laboratory comparison used historical reagents.
  • It gives no frequency after routine use.
  • The result depends on the reagent, the cutoff and the concentration in the specimen.

Tests Studied

  • Biosite Triage Benzodiazepines screen, Krasowski et al. supplement, C
  • BENZOS, row 69

Indomethacin

Source Joseph et al., J Anal Toxicol 1995

What It Found

  • Testing urine with high concentrations of indomethacin produced a signal the authors flagged as a potential cause of false-positive TDx benzodiazepine results.

Keep in Mind

  • Bench testing on a historical platform does not establish that ordinary doses cause this result on current screens.

Test Studied

  • Abbott TDx benzodiazepine fluorescence polarization immunoassay

Ketoprofen

Source Joseph et al., J Anal Toxicol 1995

What It Found

  • Testing urine with high concentrations of ketoprofen produced a signal the authors flagged as a potential cause of false-positive TDx benzodiazepine results.

Both sources Joseph et al., J Anal Toxicol 1995 Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

Keep in Mind

  • Bench testing on a historical platform does not establish that ordinary doses cause this result on current screens.

Test Studied

  • Abbott TDx benzodiazepine fluorescence polarization immunoassay

Modafinil

Source Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

What It Found

  • The 2009 comparison lists reactivity at 80,000 ng/mL for Modafinil on the Biosite Triage screen.

Keep in Mind

  • This laboratory comparison used historical reagents.
  • It gives no frequency after routine use.
  • The result depends on the reagent, the cutoff and the concentration in the specimen.

Tests Studied

  • Biosite Triage Benzodiazepines screen, Krasowski et al. supplement, C
  • BENZOS, row 71

Tolmetin

Source Joseph et al., J Anal Toxicol 1995

What It Found

  • Testing urine with high concentrations of tolmetin produced a signal the authors flagged as a potential cause of false-positive TDx benzodiazepine results.

Keep in Mind

  • Bench testing on a historical platform does not establish that ordinary doses cause this result on current screens.

Test Studied

  • Abbott TDx benzodiazepine fluorescence polarization immunoassay

Depends on the Brand of Test

Nefopam

Source Reid, J Psychopharmacol 2009

What It Found

  • In one case, repeated benzodiazepine screens became negative after nefopam was stopped.

Source Chavant et al., Toxicologie Analytique et Clinique 2020

What It Found

  • A separate patient screened positive on EMIT Atellica, while chromatography found nefopam and its metabolites and no benzodiazepine.
  • In the three-assay study, two of three treated patients’ specimens interfered on Architect, while CEDIA results were negative.

Keep in Mind

  • Adding parent nefopam to urine did not trigger EMIT Atellica at the concentrations tested.

Test Studied

  • Siemens EMIT Atellica CH, Abbott Architect MULTIGENT, Thermo CEDIA on Roche Cobas

2 sources El-Haj et al., J Anal Toxicol 2008 Chavant et al., Toxicologie Analytique et Clinique 2020

Keep in Mind

  • Metabolites may contribute, but their individual roles were not established by those spikes.

2 sources Reid, J Psychopharmacol 2009 El-Haj et al., J Anal Toxicol 2008

Test Studied

  • An earlier clinical urine immunoassay

Sertraline

2 sources Fitzgerald and Herold, J Anal Toxicol 1997 Nishikawa et al., Am J Clin Pathol 1997

What It Found

  • Sertraline metabolites cross-reacted with the original CEDIA assay.

Keep in Mind

  • The CEDIA result shows why the exact reagent version matters.

Test Studied

  • Original and reformulated CEDIA

Source Fitzgerald and Herold, J Anal Toxicol 1997

What It Found

  • The manufacturer’s improved reagent eliminated that problem in a comparative evaluation.

Source Nasky et al., Psychiatry (Edgmont) 2009

What It Found

  • Separately, a chart study found 26 sertraline prescriptions among 98 unconfirmed positive screens in people without a benzodiazepine prescription.

Keep in Mind

  • The Abbott chart study cannot estimate individual risk.

Test Studied

  • Abbott AEROSET/ARCHITECT c8000

Fenoprofen

Source Joseph et al., J Anal Toxicol 1995

What It Found

  • Testing urine with high concentrations of fenoprofen produced a signal the authors flagged as a potential cause of false-positive TDx benzodiazepine results.

Keep in Mind

  • Bench testing on a historical platform does not establish that ordinary doses cause this result on current screens.

Test Studied

  • Abbott TDx benzodiazepine fluorescence polarization immunoassay

Source Rollins et al., Clin Chem 1990

What It Found

  • A separate prospective study including people taking fenoprofen found no false-positive benzodiazepine screens.

Hydroxyzine

Source Lin-Zhi International benzodiazepine enzyme immunoassay. Hitachi 717 instructions…, 2025

What It Found

  • Lin-Zhi reports that high urine concentrations of hydroxyzine can produce a false-positive benzodiazepine screen.

Keep in Mind

  • Lin-Zhi lists hydroxyzine concentrations above 16,000 or 24,000 ng/mL, depending on the cutoff.
  • These figures describe concentrations in a urine sample.

Test Studied

  • Lin-Zhi Hitachi 717 urine assay (200 and 300 ng/mL oxazepam cutoffs)

Source Thermo Scientific DRI Benzodiazepine Assay. Instructions for use, 10025445-0-EN, 2018

What It Found

  • On the DRI assay, even 100,000 ng/mL of added hydroxyzine left the negative control negative.

Test Studied

  • Thermo Scientific DRI (200 ng/mL)

2 sources Krasowski et al., BMC Emerg Med 2009 Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

Test Studied

  • A 2009 compilation also lists negative findings for historical Beckman SYNCHRON and Biosite Triage urine benzodiazepine assays

Also cited: American Bio Medica Corporation. Rapid TOX urine drug screen product instructions…, 2009; HelloPharmacist. Can Hydroxyzine Cause A False Positive For A Benzo?, 2022

Lovastatin

Source Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

What It Found

  • The 2009 comparison lists reactivity at 100,000 ng/mL for Lovastatin on the Abbott AxSYM screen.
  • At least one other reagent in the same table showed no reaction.

Keep in Mind

  • This laboratory comparison used historical reagents.
  • It gives no frequency after routine use.
  • The result depends on the reagent, the cutoff and the concentration in the specimen.

Tests Studied

  • Abbott AxSYM Benzodiazepines screen, Krasowski et al. supplement, C
  • BENZOS, row 72

A Related Drug the Test Picks Up

Bentazepam

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Bentazepam gave relative responses of 40% (EMIT) and 15% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Flualprazolam

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Flualprazolam gave relative responses of 300% (EMIT) and 650% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Rilmazafone

Source Krasowski et al. Additional file 1. Historical assay cross-reactivity tables and reagent…, 2009

What It Found

  • The 2009 comparison lists reactivity at 500 ng/mL for Rilmazafone on the Biosite Triage screen.
  • Rilmazafone produces benzodiazepine metabolites.

Keep in Mind

  • This laboratory comparison used historical reagents.
  • It gives no frequency after routine use.
  • The result depends on the reagent, the cutoff and the concentration in the specimen.

Tests Studied

  • Biosite Triage Benzodiazepines screen, Krasowski et al. supplement, C
  • BENZOS, row 67

The Test Is Made to Find It

Alprazolam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Alprazolam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Edinboro and Poklis, J Anal Toxicol 1994

What It Found

  • An oxazepam-only confirmation can miss the metabolites targeted by broader benzodiazepine confirmation, including metabolites of Alprazolam.

Keep in Mind

  • This study addresses the coverage of the confirmation panel.
  • It does not guarantee that every screening device detects a therapeutic dose.

Test Studied

  • Biosite Triage class screen compared with Syva EMIT and an expanded GC-MS confirmation

Source Fraser and Meatherall, J Anal Toxicol 1996

What It Found

  • In the single-dose comparison the Triage device missed all urine specimens collected after Alprazolam; lowering thresholds and hydrolyzing conjugates improved detection on selected laboratory assays.

Keep in Mind

  • Expected urinary metabolites can be present even when a benzodiazepine class screen is negative.

Test Studied

  • EMIT d.a.u., EMIT II, TDx, Biosite Triage, and Microgenics CEDIA

Source Torikoshi et al., Chudoku Kenkyu 2014

What It Found

  • The strip recognized the 4-hydroxy metabolite of Alprazolam but missed the corresponding alpha-hydroxy metabolite in its challenge panel.

Keep in Mind

  • The detection pattern belongs to the specific strip and metabolites tested.

Test Studied

  • Instant-View M-1 urine screen

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 93% for alprazolam and 92% for its alpha-hydroxy metabolite relative response.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Clonazepam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Clonazepam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • The test reacted much less strongly to 7-aminoclonazepam, the major urine metabolite, than to the parent drug.
  • A negative screen can therefore miss an exposure.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Abduljabbar et al., Luminescence 2024

What It Found

  • Participants excreted the genuine 7-amino metabolite after receiving clonazepam.

Keep in Mind

  • The investigators used a dedicated assay.
  • This is not a sensitivity estimate for a routine benzodiazepine screen.

Test Studied

  • Dedicated urine spectrofluorimetric measurement of 7-aminoclonazepam

Source Rossi et al., Molecules 2021

What It Found

  • The ARK assay was more responsive for lorazepam, 7-aminoclonazepam and oxazepam than the comparison assay in single-analyte clinical specimens.

Keep in Mind

  • The number of individually positive urines for each analyte was small.

Test Studied

  • EMIT II Plus and ARK HS Benzodiazepine II in authentic patient urine

Source Tolan et al., J Mass Spectrom Adv Clin Lab 2024

What It Found

  • The newer BNZ2 method improved detection of lorazepam and clonazepam metabolites in urine from the emergency department and a compliance-monitoring program.

Keep in Mind

  • Even the newer assay missed some LC-MS/MS-positive specimens.

Test Studied

  • Roche BENZ and Benzodiazepines II (BNZ2) compared with LC-MS/MS

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 75% for clonazepam and 58% for its 7-amino metabolite relative response.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Clonazolam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Clonazolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Clonazolam gave relative responses of 100% (EMIT) and 40% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Deschloroetizolam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Deschloroetizolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Diclazepam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Diclazepam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Diclazepam gave relative responses of >1,000% (EMIT) and >1,000% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Estazolam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Estazolam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Estazolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Etizolam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Etizolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Source Beck et al., Drug Test Anal 2014

What It Found

  • At a Etizolam spike of 115 ng/mL, the mean assay response was 272 ng/mL equivalent (237% cross-reactivity), above the 200 ng/mL cutoff.

Keep in Mind

  • This is a mean laboratory signal at the stated concentration.
  • The separate clinical urine findings can include metabolites or coexposures.

Test Studied

  • CEDIA Benzodiazepines urine assay, cutoff 200 ng/mL

Source Torikoshi et al., Chudoku Kenkyu 2014

What It Found

  • Instant-View M-1 failed to detect etizolam and 7-amino metabolites such as 7-aminonitrazepam in this study.

Keep in Mind

  • A negative class screen can miss genuine use.
  • Other assays can behave differently.

Test Studied

  • Instant-View M-1 benzodiazepines strip

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Etizolam gave relative responses of 60% (EMIT) and 100% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Flubromazepam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Flubromazepam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Flubromazolam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Flubromazolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Flubromazolam gave relative responses of 300% (EMIT) and 400% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 91% relative response to Flubromazolam.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Flunitrazepam

Source Snyder et al., J Anal Toxicol 2001

What It Found

  • After a single 2 mg dose SBENZ detected more serial urine samples than TDx.
  • The authors attributed the difference partly to recognition of 7-aminoflunitrazepam.

Keep in Mind

  • Four volunteers contributed serial samples.
  • These counts do not estimate a population detection rate.

Test Studied

  • COBAS INTEGRA SBENZ, Abbott TDx benzodiazepines and GC-MS

Source Bertol et al., J Pharm Biomed Anal 2013

What It Found

  • The investigators found weak responses for 3-hydroxyflunitrazepam, 7-aminonitrazepam and alpha-hydroxymidazolam, the metabolites evaluated from these respective drugs.

Keep in Mind

  • The result concerns the named metabolite.
  • It does not prove the parent or every other metabolite will be missed.

Test Studied

  • EMIT II Plus Benzodiazepine assay

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 68% for flunitrazepam and 66% for its 7-amino metabolite relative response.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Flurazepam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Flurazepam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Edinboro and Poklis, J Anal Toxicol 1994

What It Found

  • An oxazepam-only confirmation can miss the metabolites targeted by broader benzodiazepine confirmation, including metabolites of Flurazepam.

Keep in Mind

  • This study addresses the coverage of the confirmation panel.
  • It does not guarantee that every screening device detects a therapeutic dose.

Test Studied

  • Biosite Triage class screen compared with Syva EMIT and an expanded GC-MS confirmation

Source Laurie et al., Analyst 1996

What It Found

  • The investigators found no appreciable reaction to Flurazepam at concentrations reported in urine on this experimental antibody.

Keep in Mind

  • Detection of a parent drug differs from detection of its metabolites.

Test Studied

  • Experimental mouse anti-oxazepam ELISA

Flutazolam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Flutazolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Lorazepam

Source Swartchick et al., Clin Biochem 2026

What It Found

  • Definitive testing confirmed lorazepam in urine.
  • After the laboratory changed to BNZ2, the screen detected more of the glucuronidated benzodiazepine and more lorazepam-only specimens.

Keep in Mind

  • The same reformulation also produced more screens that did not confirm.
  • The study did not identify which unrelated medicines caused them.

Test Studied

  • Roche BENZ Plus and reformulated BNZ2 on cobas pro c503

Source Lund et al., J Mass Spectrom Adv Clin Lab 2023

What It Found

  • Adding hydrolysis improved detection of lorazepam glucuronide in urine.
  • After introduction of the modified Roche method the laboratory saw more confirmed lorazepam results.

Keep in Mind

  • Sensitivity varies by reagent and cutoff.
  • A negative class screen can occur despite an actual prescription exposure.

Test Studied

  • High-sensitivity Thermo CEDIA and laboratory-modified Roche Benzodiazepines Plus with beta-glucuronidase, compared with LC-MS/MS

Source Ge et al., J Appl Lab Med 2024

What It Found

  • The hydrolysis-capable assays detected glucuronidated benzodiazepines more sensitively than Benzodiazepines Plus in urine.

Keep in Mind

  • These assays differ in how they recognize lorazepam glucuronide.
  • A negative screen can miss treatment exposure.

Test Studied

  • Roche Benzodiazepines II and Plus and a high-sensitivity laboratory-developed immunoassay, 200 ng/mL nordiazepam cutoff

Source Way et al., Clin Chim Acta 1998

What It Found

  • In 500 submitted urines, the CEDIA assay was more sensitive to lorazepam than EMIT II.

Keep in Mind

  • Not every sample testing negative on both assays underwent confirmation.

Test Studied

  • CEDIA and EMIT II on Hitachi 747

Source Klette et al., J Anal Toxicol 2005

What It Found

  • The glucuronide of Lorazepam showed less than 1% reactivity without hydrolysis and 20% after hydrolysis in this study.

Keep in Mind

  • This concerns expected benzodiazepine detection, including why a screen may miss a real exposure.

Test Studied

  • Roche Online KIMS with and without beta-glucuronidase, nordiazepam cutoff 100 ng/mL

Source Rossi et al., Molecules 2021

What It Found

  • The ARK assay was more responsive for lorazepam, 7-aminoclonazepam and oxazepam than the comparison assay in single-analyte clinical specimens.

Keep in Mind

  • The number of individually positive urines for each analyte was small.

Test Studied

  • EMIT II Plus and ARK HS Benzodiazepine II in authentic patient urine

Source Tolan et al., J Mass Spectrom Adv Clin Lab 2024

What It Found

  • The newer BNZ2 method improved detection of lorazepam and clonazepam metabolites in urine from the emergency department and a compliance-monitoring program.

Keep in Mind

  • Even the newer assay missed some LC-MS/MS-positive specimens.

Test Studied

  • Roche BENZ and Benzodiazepines II (BNZ2) compared with LC-MS/MS

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 70% relative response to Lorazepam.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Meclonazepam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Meclonazepam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Nifoxipam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Nifoxipam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Oxazepam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Oxazepam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Klette et al., J Anal Toxicol 2005

What It Found

  • The glucuronide of Oxazepam showed less than 1% reactivity without hydrolysis and 15% after hydrolysis in this study.

Keep in Mind

  • This concerns expected benzodiazepine detection, including why a screen may miss a real exposure.

Test Studied

  • Roche Online KIMS with and without beta-glucuronidase, nordiazepam cutoff 100 ng/mL

Source Rossi et al., Molecules 2021

What It Found

  • The ARK assay was more responsive for lorazepam, 7-aminoclonazepam and oxazepam than the comparison assay in single-analyte clinical specimens.

Keep in Mind

  • The number of individually positive urines for each analyte was small.

Test Studied

  • EMIT II Plus and ARK HS Benzodiazepine II in authentic patient urine

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 76% relative response to Oxazepam.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Phenazepam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Phenazepam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Source Rossi et al., Molecules 2021

What It Found

  • In the two fortified-urine assays, Phenazepam gave relative responses of 200% (EMIT) and >1,000% (ARK).

Keep in Mind

  • These are responses relative to different assay calibrators.
  • They do not establish the risk of a positive in a particular individual.

Test Studied

  • Siemens EMIT II Plus Benzodiazepine and ARK HS Benzodiazepine II, Table 3

Pyrazolam

Source Pettersson Bergstrand et al., Drug Test Anal 2017

What It Found

  • The investigators challenged the assays with Pyrazolam as a benzodiazepine-class analyte.
  • Recognition across the panel was generally strong but depended on reagent; flutazolam was the least detectable of the parent compounds.

Keep in Mind

  • A narrow confirmatory panel may omit these compounds.
  • The abstract does not give a drug-specific cutoff on each individual device.

Test Studied

  • CEDIA, EMIT II Plus, HEIA and KIMS II urine benzodiazepine assays

Temazepam

Source Piergies et al., Arch Pathol Lab Med 1997

What It Found

  • The benzodiazepine temazepam served as the positive control.
  • A single oral dose produced positive results in some volunteers.

Keep in Mind

  • Detection varied by method and collection time.
  • An expected positive does not mean every sample will screen positive.

Test Studied

  • Syva EMIT II and Abbott ADx

Source Klette et al., J Anal Toxicol 2005

What It Found

  • The glucuronide of Temazepam showed less than 1% reactivity without hydrolysis and 25% after hydrolysis in this study.

Keep in Mind

  • This concerns expected benzodiazepine detection, including why a screen may miss a real exposure.

Test Studied

  • Roche Online KIMS with and without beta-glucuronidase, nordiazepam cutoff 100 ng/mL

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 82% relative response to Temazepam.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Triazolam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Triazolam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Edinboro and Poklis, J Anal Toxicol 1994

What It Found

  • An oxazepam-only confirmation can miss the metabolites targeted by broader benzodiazepine confirmation, including metabolites of Triazolam.

Keep in Mind

  • This study addresses the coverage of the confirmation panel.
  • It does not guarantee that every screening device detects a therapeutic dose.

Test Studied

  • Biosite Triage class screen compared with Syva EMIT and an expanded GC-MS confirmation

Source Fraser and Meatherall, J Anal Toxicol 1996

What It Found

  • In the single-dose comparison the Triage device missed all urine specimens collected after Triazolam; lowering thresholds and hydrolyzing conjugates improved detection on selected laboratory assays.

Keep in Mind

  • Expected urinary metabolites can be present even when a benzodiazepine class screen is negative.

Test Studied

  • EMIT d.a.u., EMIT II, TDx, Biosite Triage, and Microgenics CEDIA

Source Torikoshi et al., Chudoku Kenkyu 2014

What It Found

  • The strip recognized the 4-hydroxy metabolite of Triazolam but missed the corresponding alpha-hydroxy metabolite in its challenge panel.

Keep in Mind

  • The detection pattern belongs to the specific strip and metabolites tested.

Test Studied

  • Instant-View M-1 urine screen

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 69% relative response to Triazolam.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Clobazam

Source Hughey and Colby, Clin Chem 2019

What It Found

  • The screening assay detected clobazam, a prescribed benzodiazepine.
  • The center’s confirmation panel omitted it, creating apparent false positives.

Keep in Mind

  • Ask which specific benzodiazepines and metabolites were included in the confirmation panel.

Test Studied

  • Local urine benzodiazepine screen and targeted definitive panel in Vanderbilt study

Bromazepam

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 110% for bromazepam and 75% for its alpha-hydroxy metabolite relative response.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Brotizolam

Source Bertol et al., J Pharm Biomed Anal 2013

What It Found

  • Brotizolam was among the more reactive benzodiazepines in this six-compound comparison using LC-MS/MS-verified spiked urine.

Keep in Mind

  • Recognition of a benzodiazepine by a class test is expected.
  • Detection still depends on urine concentration.

Test Studied

  • EMIT II Plus Benzodiazepine assay

Chlordiazepoxide

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Chlordiazepoxide belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Laurie et al., Analyst 1996

What It Found

  • The investigators found no appreciable reaction to Chlordiazepoxide at concentrations reported in urine on this experimental antibody.

Keep in Mind

  • Detection of a parent drug differs from detection of its metabolites.

Test Studied

  • Experimental mouse anti-oxazepam ELISA

Clorazepate

Both sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Clorazepate belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Delorazepam

Source Bertol et al., J Pharm Biomed Anal 2013

What It Found

  • Delorazepam was among the more reactive benzodiazepines in this six-compound comparison using LC-MS/MS-verified spiked urine.

Keep in Mind

  • Recognition of a benzodiazepine by a class test is expected.
  • Detection still depends on urine concentration.

Test Studied

  • EMIT II Plus Benzodiazepine assay

Diazepam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Diazepam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Beyer and Martz, Arch Pharm (Weinheim) 1991

What It Found

  • Diazepam showed stronger recognition than the other 33 benzodiazepine relatives compared with the reference compound, nordiazepam.

Keep in Mind

  • The result describes one historical antibody and cannot establish urine detection after a given dose.

Test Studied

  • Abbott TDx, benchmarked against 200 ng/mL nordiazepam

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 87% for diazepam and 100% for nordiazepam relative response.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Midazolam

2 sources FDA 510(k) decision summary for Quidel Triage TOX Drug Screen, K182719. Analytical…, 2019 Krasowski et al., BMC Emerg Med 2009

What It Found

  • Midazolam belongs to the benzodiazepine class and is among the drugs that reacted in urine in the FDA-reviewed assay data.

Keep in Mind

  • Assays differ in sensitivity to the parent medicine and its metabolites.
  • A class-positive result does not identify which benzodiazepine was taken.

Test Studied

  • Quidel Triage TOX urine benzodiazepine assay

Source Bertol et al., J Pharm Biomed Anal 2013

What It Found

  • The investigators found weak responses for 3-hydroxyflunitrazepam, 7-aminonitrazepam and alpha-hydroxymidazolam, the metabolites evaluated from these respective drugs.

Keep in Mind

  • The result concerns the named metabolite.
  • It does not prove the parent or every other metabolite will be missed.

Test Studied

  • EMIT II Plus Benzodiazepine assay

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded 84% for midazolam and 82% for its alpha-hydroxy metabolite relative response.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Nitrazepam

Source Bertol et al., J Pharm Biomed Anal 2013

What It Found

  • The investigators found weak responses for 3-hydroxyflunitrazepam, 7-aminonitrazepam and alpha-hydroxymidazolam, the metabolites evaluated from these respective drugs.

Keep in Mind

  • The result concerns the named metabolite.
  • It does not prove the parent or every other metabolite will be missed.

Test Studied

  • EMIT II Plus Benzodiazepine assay

Source Torikoshi et al., Chudoku Kenkyu 2014

What It Found

  • Instant-View M-1 failed to detect etizolam and 7-amino metabolites such as 7-aminonitrazepam in this study.

Keep in Mind

  • A negative class screen can miss genuine use.
  • Other assays can behave differently.

Test Studied

  • Instant-View M-1 benzodiazepines strip

Pinazepam

Source Bertol et al., J Pharm Biomed Anal 2013

What It Found

  • Pinazepam was among the more reactive benzodiazepines in this six-compound comparison using LC-MS/MS-verified spiked urine.

Keep in Mind

  • Recognition of a benzodiazepine by a class test is expected.
  • Detection still depends on urine concentration.

Test Studied

  • EMIT II Plus Benzodiazepine assay

Tested: No False Positive Found

Zolpidem

Source Piergies et al., Arch Pathol Lab Med 1997

What It Found

  • Healthy volunteers given 10 mg of zolpidem had negative benzodiazepine screens on both systems during the following day.

Keep in Mind

  • Zolpidem is a nonbenzodiazepine sleeping medicine.
  • These findings are specific to the two platforms and dose.

Test Studied

  • Syva EMIT II and Abbott ADx

Source Neukamm et al., Drug Test Anal 2017

What It Found

  • The modified assay yielded less than 0.01% relative response to Zolpidem.

Keep in Mind

  • The study spiked a negative calibrator for a modified, low-cutoff urine screening program.
  • Relative assay response does not by itself demonstrate a false positive after a prescribed dose or apply to all Roche reagents.

Test Studied

  • Modified Roche KIMS benzodiazepines urine application on cobas c 501, Table 4

Flumazenil

Source Martens et al., J Toxicol Clin Toxicol 1990

What It Found

  • Investigators tested whether flumazenil or its metabolites interfered with benzodiazepine screening.
  • They reported no interference on the three methods studied, including testing after oral flumazenil.

Keep in Mind

  • The result covers the historical assays in the study.
  • Patients given flumazenil after a benzodiazepine overdose can still have the original benzodiazepine present.

Test Studied

  • EMIT, TDx and radioimmunoassay benzodiazepine screens

Acetaminophen

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Acetaminophen at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Dextromethorphan

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Dextromethorphan at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Diphenhydramine

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Diphenhydramine at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Meprobamate

Source Lin et al., J Anal Toxicol 2013

What It Found

  • The authors observed no interference from Meprobamate at 1,000 ng/mL when it was added to drug-free urine for the cup comparison.

Keep in Mind

  • This is a single challenge level.
  • It cannot rule out interference at a higher concentration or with a different device.

Test Studied

  • NexScreen and DrugCheck Waive RT cups, as applicable to their respective panels

Prednisone

Source FDA 510(k) K253567. Healgen Accurate Urine Drug Screen Dip Card and Home Urine Drug Test…, 2025

What It Found

  • Prednisone at 100 µg/mL did not cause a positive result in drug-free urine or change the result of urine just below or above this channel’s cutoff.

Keep in Mind

  • The manufacturer challenged the assay with parent prednisone.
  • This does not test all prednisone metabolites or predict the behavior of other devices.

Tests Studied

  • Healgen Accurate multi-drug urine dip card
  • The applicable target and cutoff are 300 ng/mL oxazepam